Regenera receives ethics approval for second clinical trial

By Renate Krelle
Wednesday, 20 October, 2004

Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.

Visagen is a preservative free formulation of the steroid triamcinolone acetonide.

The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.

Giving rotavirus vaccine at birth benefits gut bacteria

Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...

TGA approves donanemab for treatment of early Alzheimer's

The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...

Ultra-processed foods linked to poor health, premature death

Evidence suggests a dose-response relationship between ultra-processed food consumption and...

Content from other channels on our network

Injectable tech for fresh produce could extend shelf life

Manufacturing most impacted by ransomware in Q1 2025

Balancing packaging waste and food waste through data-driven design

Call for comment on thermolysin as a processing aid

No kidding: Australia's goatmeat exports at all-time high

Making surgery safer with an Australian-first perioperative medicines resource

Digital displays in health care: benefits for patients and staff

Doctors' warning — Bupa's plans risk a US-style health model

NSWNMA: Proposed workers comp changes a "cruel blow"

Nursing and Midwifery Board waives renewal late fee until 15 June

CeMAT 2025 incorporates processing, packaging and more

WA Government investing $500 million to unlock industrial areas

Homegrown solar pioneer first to be funded for Solar Sunshot

Researchers show robots how to identify an object's properties through handling

UAE-funded consortium to build a waste‍-‍to‍-‍energy facility in Parkes